SQUAWK/NEWS
Account
Account
Menu
Live News REGULATION FLASH M impact

Ascelia Pharma FDA schedules Type A meeting for Orviglance NDA Sep 9, 2026

Ascelia Pharma says the FDA has scheduled a Type A meeting for its Orviglance NDA on September 9, 2026.

ACE

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.